Corticosteroid co-treatment induces resistance to chemotherapy in surgical resections, xenografts and established cell lines of pancreatic cancer
Authors:
- Chengwen ZhangCZChengwen Zhang
- Armin KolbAKArmin Kolb
- Peter BüchlerPBPeter Büchler
- Andrew Cb CatoACAndrew Cb Cato
- Jürgen MatternJMJürgen Mattern
- Werner RittgenWRWerner Rittgen
- Lutz EdlerLELutz Edler
- Klaus-Michael DebatinKDKlaus-Michael Debatin
- Markus W BüchlerMBMarkus W Büchler
- Helmut FriessHFHelmut Friess
- Ingrid HerrIHIngrid Herr
Open Access
- 15 March 2006
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 6 (1) , 61
Abstract
Background: Chemotherapy for pancreatic carcinoma often has severe side effects that limit its efficacy. The glucocorticoid (GC) dexamethasone (DEX) is frequently used as co-treatment to prevent side effects of chemotherapy such as nausea, for palliative purposes and to treat allergic reactions. While the potent pro-apoptotic properties and the supportive effects of GCs to tumour therapy in lymphoid cells are well studied, the impact of GCs to cytotoxic treatment of pancreatic carcinoma is unknown. Methods: A prospective study of DEX-mediated resistance was performed using a pancreatic carcinoma xenografted to nude mice, 20 surgical resections and 10 established pancreatic carcinoma cell lines. Anti-apoptotic signaling in response to DEX was examined by Western blot analysis. Results: In vitro, DEX inhibited drug-induced apoptosis and promoted the growth in all of 10 examined malignant cells. Ex vivo, DEX used in physiological concentrations significantly prevented the cytotoxic effect of gemcitabine and cisplatin in 18 of 20 freshly isolated cell lines from resected pancreatic tumours. No correlation with age, gender, histology, TNM and induction of therapy resistance by DEX co-treatment could be detected. In vivo, DEX totally prevented cytotoxicity of chemotherapy to pancreatic carcinoma cells xenografted to nude mice. Mechanistically, DEX upregulated pro-survival factors and anti-apoptotic genes in established pancreatic carcinoma cells. Conclusion: These data show that DEX induces therapy resistance in pancreatic carcinoma cells and raise the question whether GC-mediated protection of tumour cells from cancer therapy may be dangerous for patients.Keywords
This publication has 33 references indexed in Scilit:
- Dexamethasone desensitizes hepatocellular and colorectal tumours toward cytotoxic therapyCancer Letters, 2006
- Corticosteriod-induced chemotherapy resistance in urological cancersCancer Biology & Therapy, 2006
- Glucocorticoid administration in antiemetic therapy: Is it safe?Cancer, 2005
- Glucocorticoid administration in antiemetic therapyCancer, 2004
- Skin Cancers and Non-Hodgkin Lymphoma Among Users of Systemic Glucocorticoids: A Population-Based Cohort StudyJNCI: Journal of the National Cancer Institute, 2004
- A phase II study of mitomycin C, cisplatin and protracted infusional 5-fluorouracil in advanced pancreatic carcinoma: efficacy and low toxicityAnnals of Oncology, 2003
- Molecular Determinants for the Tissue Specificity of SERMsScience, 2002
- Glucocorticoid-Induced Apoptosis in LymphocytesBiochemical and Biophysical Research Communications, 2000
- Steroid Antiemesis May Be HarmfulNew England Journal of Medicine, 1981
- THE INFLUENCE OF CORTICOID STEROIDS ON THE FREQUENCY OF SPLEEN METASTASES IN PATIENTS WITH BREAST CANCERActa Pathologica Microbiologica Scandinavica, 1958